Synonym
AT090; AT 090; AT-090
IUPAC/Chemical Name
1-(1-((1s,4s)-4-iso-propylcyclohexyl)piperidin-4-yl)indoline-2,3-dione
InChi Key
RCRPVEANWGMGSQ-CALCHBBNSA-N
InChi Code
InChI=1S/C22H30N2O2/c1-15(2)16-7-9-17(10-8-16)23-13-11-18(12-14-23)24-20-6-4-3-5-19(20)21(25)22(24)26/h3-6,15-18H,7-14H2,1-2H3/t16-,17+
SMILES Code
O=C1N(C2CCN([C@H]3CC[C@@H](C(C)C)CC3)CC2)C4=C(C=CC=C4)C1=O
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
354.49
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Denys IB, Gao J, Sutphen JC, Zaveri NT, Kapusta DR. Cardiovascular and renal
effects of novel nonpeptide nociceptin opioid peptide receptor agonists. Br J
Pharmacol. 2022 Jan;179(2):287-300. doi: 10.1111/bph.15717. Epub 2021 Dec 12.
PMID: 34705263; PMCID: PMC8716424.
2: Ferrari F, Cerlesi MC, Malfacini D, Asth L, Gavioli EC, Journigan BV,
Kamakolanu UG, Meyer ME, Yasuda D, Polgar WE, Rizzi A, Guerrini R, Ruzza C,
Zaveri NT, Calo G. In vitro functional characterization of novel
nociceptin/orphanin FQ receptor agonists in recombinant and native preparations.
Eur J Pharmacol. 2016 Dec 15;793:1-13. doi: 10.1016/j.ejphar.2016.10.025. Epub
2016 Oct 22. PMID: 27780725; PMCID: PMC5555400.
3: Asth L, Ruzza C, Malfacini D, Medeiros I, Guerrini R, Zaveri NT, Gavioli EC,
Calo' G. Beta-arrestin 2 rather than G protein efficacy determines the
anxiolytic-versus antidepressant-like effects of nociceptin/orphanin FQ receptor
ligands. Neuropharmacology. 2016 Jun;105:434-442. doi:
10.1016/j.neuropharm.2016.02.003. Epub 2016 Feb 8. PMID: 26867504; PMCID:
PMC5567672.
4: Silva EF, Silva AI, Asth L, Souza LS, Zaveri NT, Guerrini R, Calo' G, Ruzza
C, Gavioli EC. Nociceptin/orphanin FQ receptor agonists increase aggressiveness
in the mouse resident-intruder test. Behav Brain Res. 2019 Jan 1;356:120-126.
doi: 10.1016/j.bbr.2018.08.019. Epub 2018 Aug 22. PMID: 30142397.
5: Asth L, Tiago PRF, Costa LRF, Holanda VAD, Pacifico S, Zaveri NT, Calo' G,
Ruzza C, Gavioli EC. Effects of non-peptide nociceptin/orphanin FQ receptor
ligands on methylphenidate-induced hyperactivity in mice: Implications for
bipolar disorders. Neuropeptides. 2020 Aug;82:102059. doi:
10.1016/j.npep.2020.102059. Epub 2020 Jun 15. PMID: 32600667.
